Royce practices food and drug law with a focus on advising pharmaceutical, medical device, cannabis, dietary supplement, tobacco, food and beverage companies as well as investment firms on a range of regulatory matters. He is presently the co-lead of the Cannabis, Hemp, and CBD industry team.
Royce has experience handling complex issues that arise in industries regulated by FDA, USDA, DEA, FTC, EPA, state cannabis regulators, board of pharmacy, Alcohol and Tobacco Tax and Trade Bureau (TTB), and United States Centers for Medicare and Medicaid (CMS).
He has worked with businesses on complex issues regarding drug and food labeling, cannabis compliance, product recalls, food contamination, theft of controlled substances, importation of drugs and medical devices, and criminal violations of the Food Drug and Cosmetics Act (FDCA). Royce has significant experience with FDA enforcement matters responses including crafting response strategies for FDA inspection Form 483’s and Warning Letters.
Both as a former in house attorney and as a member of the firm’s life sciences team Royce works with pharmaceutical and device companies regarding product promotion, labeling, unapproved drugs, competitor products, NDAs, ANDAs, Over The Counter (OTC) drugs, securities filings, clinical trials, drug pricing, federal supply schedules, PhRMA Code and AdvaMed Code compliance, and board of pharmacy registrations.
Royce is plugged in on the ground level in the evolving legal landscape of cannabis and controlled substances. Advising clients on issues pertaining to cannabis transactions, state regulation, product labeling, operational compliance, banking, for direct and indirect Cannabis related industries including CBD, Hemp, and Marijuana product. He has advised and aided numerous banks in crafting policies and procedures for this emerging industry.
Prior to joining McGuireWoods, Royce served as an extern at INTERPOL, the EPA Office of Enforcement and Compliance Assurance (OECA), worked for an Institutional Review Board (IRB) and served as the Associate Counsel for Regulatory Affairs at a drug, medical device, and dietary supplement company. In this position, he oversaw all regulatory aspects from manufacture to marketing of the company’s products, including overseeing four successful branded pharmaceutical product launches. Royce presently advises on a range of issues including;
His past in-house experience gives him insight into the complex mechanics and challenges healthcare and life sciences companies face in growth, compliance, supply, marketing, and manufacturing. He blends legal strategy with business sense to construct practical solutions that match the needs of clients in these heavily regulated industries.
In addition to his current practice, Royce handles pro bono cases for veterans in order to seek benefits for injuries sustained in service and correct service records.
"My time spent in industry gives me a business minded approach to law and my clients. By knowing the client’s business and caring about their products I am able to solve legal issues to advance the business solution."
Advised underwriters B. Riley Securities Inc. and Roth Capital Partners in a $35.2 million IPO of Journey Medical Corp.
Representation of B. Riley FBR, Inc. (formerly FBR Capital Markets & Co.) as placement agent in connection with the extension of its existing relationship with Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company.
Representation of Alliance Global Partners (AGP), a regional investment and advisory firm providing investment advisory and brokerage services to individuals and institutions, in connection with the launch of an at-the-market program in which AGP serves as placement agent to ProPhase Labs, Inc. (Nasdaq: PRPH), a manufacturing and marketing company with experience with OTC consumer healthcare products and dietary supplements.
Representation of National Securities Corp., acting as exclusive placement agent, in connection with a private offering and sale of preferred stock by Cyprium Therapeutics, Inc., a clinical-stage biopharmaceutical company.
Advised multiple banks on requirements and federal law for banking Marijuana and Hemp businesses.
Aided in the drafting and review of Premarket Tobacco Application (PMTA) for a novel nicotine product for modified risk use tobacco product.
Organized document review and designed policies for large scale advocacy project for redaction of confidential client information within FDA applications under Freedom of Information Act (FOIA) exemptions.
Filed and aided on issues of FOIA in litigation.
Managed USDA and FDA diligence for the successful acquisition of a national manufacturer of snack products.
Assisted in state and local food safety compliance diligence for the successful acquisition of national restaurant chains.
Designed compliance programs for emerging plant based food products for a major international manufacturer.
Added in the security filing review for multiple publicly traded companies with regards to their statements involving drug efficacy, clinical trials, and competition.
Drafted policies and procedures for medical device, food, beverage, and pharmaceutical companies.
Served as regulatory counsel on class action food product liability litigation involving allegations of consumer fraud.
Advised multiple publicly traded life sciences companies and private equity funds in mergers and acquisitions, conducting comprehensive due diligence to spot and correct problems.
Lead the legal review for the joint-development of a biosimilar.
Advised on hemp and hemp extract products at the state and federal levels.
Advised food and beverage companies for the manufacture of Over The Counter (OTC) hand sanitizer during the COVID-19 Emergency.
Added in importation of medical devices, masks, and drugs during the COVID-19 Emergency and associated issues with United States Customs and Border Protection (CBP).
Registered and listed multiple companies and their products on FDA CDER Direct and FURLS.
Assisted as regulatory counsel in the defense of criminal violations of the Food, Drug, and Cosmetics Act.
Provided guidance and resolved issues arising with suspected carcinogenic chemicals in human food.
Represented companies before FDA on issues of drug recall, importation, and product compliance.
Solved state licensure issues for manufacturers and wholesalers of drug products before state board of pharmacy.
Trained pharmaceutical sales representatives on current law as it relates to the promotion of drug products.
Aided defense team as regulatory counsel on a drug product liability claim involving birth-defect.
Effected change at the local level and in public meetings advocating for policies to advance the ability to market pharmaceutical products.
Advised on prescription and over the counter drug and dietary supplement labels, labeling, and promotion as the legal representative for the promotional review committee of a pharmaceutical company, overseeing all promotional materials and product labeling.
Regulatory counsel on five separate Lanham Act cases involving false claims for drug and dietary supplement products.
Negotiated pharmaceutical wholesale drug sale agreements and purchase agreements for raw materials enabling sales team to $200 million dollar sales targets.
Created a comprehensive product legal and regulatory database for company for current products and labeling.
Founding Member, The Psychedelic Bar Association
Member, Editorial Advisory Board, FDLI Update, Food and Drug Law Institute, 2020-present
Named a "Cannabis Law Trailblazer", The National Law Journal, 2020
McGuireWoods Advises Biofrontera Inc. in Multimillion-Dollar IPO and Subsequent Private Placement
December 6, 2021
McGuireWoods Advises Underwriters in $35 Million IPO of Journey Medical Corp.
November 16, 2021
McGuireWoods Advises Cronos Group on Strategic Investment in PharmaCann
August 30, 2021